Dongping Wei
Impact in
- Biotechnology top 5%
- Cancer Research and Treatments
- Oncology top 5%
- Cancer-related Molecular Pathways
- PARP inhibition in cancer therapy
Papers in
-
- Ubiquitin and proteasome pathways 12
- RNA modifications and cancer 5
- Protein Degradation and Inhibitors 4
- DNA Repair Mechanisms 4
- Oncology 13
- Cancer-related Molecular Pathways 8
- Co-authors
- Lili Zhao (6 shared papers)Yi Sun (9 shared papers)Meredith A. Morgan (7 shared papers)Theodore S. Lawrence (5 shared papers)Leslie A. Parsels (4 shared papers)David Karnak (3 shared papers)Jonathan Maybaum (3 shared papers)Mary A. Davis (3 shared papers)
- Journals
- Clinical Cancer Research (3 papers)Molecular & Cellular Proteomics (2 papers)Translational Oncology (2 papers)Cancer Science (2 papers)Oncogene (2 papers)
- Partner nations
- ChinaUnited StatesAustralia
In The Last Decade
Dongping Wei
33 papers receiving 1.2k citations
Peers
Comparison fields: 5 of 83
- Biotechnology 164
- Oncology 472
- Cancer Research 198
- Molecular Biology 870
- Cell Biology 113
Countries citing papers authored by Dongping Wei
This map shows the geographic impact of Dongping Wei's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dongping Wei with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dongping Wei more than expected).
Fields of papers citing papers by Dongping Wei
This network shows the impact of papers produced by Dongping Wei. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dongping Wei. The network helps show where Dongping Wei may publish in the future.
Co-authors
The 25 scholars most cited alongside Dongping Wei, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 33 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2011 | 136 | |
| 2 | 2014 | 125 | |
| 3 | 2013 | 89 | |
| 4 | 2013 | 80 | |
| 5 | 2018 | 80 | |
| 6 | 2014 | 74 | |
| 7 | 2007 | 57 | |
| 8 | 2007 | 52 | |
| 9 | 2014 | 46 | |
| 10 | 2014 | 45 | |
| 11 | 2015 | 44 | |
| 12 | 2015 | 43 | |
| 13 | 2022 | 39 | |
| 14 | 2009 | 39 | |
| 15 | 2019 | 38 | |
| 16 | 2019 | 36 | |
| 17 | 2015 | 30 | |
| 18 | 2011 | 28 | |
| 19 | 2021 | 28 | |
| 20 | 2015 | 23 |
About Dongping Wei
Dongping Wei is a scholar working on Molecular Biology, Oncology, Epidemiology, Biotechnology and Cancer Research, having authored 33 papers that have together received 1.2k indexed citations. Recurring topics across this work include Ubiquitin and proteasome pathways (12 papers), Cancer-related Molecular Pathways (8 papers), Nanoplatforms for cancer theranostics (5 papers), Cancer Research and Treatments (5 papers), RNA modifications and cancer (5 papers), Protein Degradation and Inhibitors (4 papers), Cancer, Hypoxia, and Metabolism (4 papers) and DNA Repair Mechanisms (4 papers). The work is most often cited by research in Biotechnology (164 citations), Oncology (472 citations), Cancer Research (198 citations), Molecular Biology (870 citations) and Cell Biology (113 citations). Dongping Wei has collaborated with scholars based in China, United States and Australia. Frequent co-authors include Lili Zhao, Yi Sun, Meredith A. Morgan, Theodore S. Lawrence, Leslie A. Parsels, David Karnak, Jonathan Maybaum, Mary A. Davis, Lijun Jia and Yongchao Zhao. Their work appears in journals such as Clinical Cancer Research, Molecular & Cellular Proteomics, Translational Oncology, Cancer Science and Oncogene.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.